Evidence map›Paper›PMID 38275825›Full record

ArticleCells2024

Exploring the Potential of Montmorillonite as an Antiproliferative Nanoagent against MDA-MB-231 and MCF-7 Human Breast Cancer Cells.

Alireza Ghannad Sabzevari, Hossein Sabahi, Mohsen Nikbakht, Mehdi Azizi, Hassan Dianat-Moghadam, Zohreh Amoozgar

Open access · goldAbstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Alireza Ghannad SabzevariDepartment of Tissue Engineering and Biomaterials, Faculty of Advanced Medical Sciences and Technologies, Hamadan University of Medical Sciences, Hamadan 6517838736, Iran.ORCID 0000-0001-9118-6741
Hossein SabahiDepartment of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran 1439957131, Iran.ORCID 0000-0002-5245-988X
Mohsen NikbakhtHematology Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran 1411713135, Iran.
Mehdi AziziDepartment of Tissue Engineering and Biomaterials, Faculty of Advanced Medical Sciences and Technologies, Hamadan University of Medical Sciences, Hamadan 6517838736, Iran.
Hassan Dianat-MoghadamDepartment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran.ORCID 0000-0002-5946-6943
Zohreh AmoozgarEdwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Hamedan University of Medical Sciences · IRHarvard University · USIsfahan University of Medical Sciences · IRTehran University of Medical Sciences · IRUniversity of Tehran · IR

Funding

Shariati Hospital 96-02-36-35047
6 · The paper itself

Abstract

Unlike MCF-7 cells, MDA-MB-231 cells are unresponsive to hormone therapy and often show resistance to chemotherapy and radiotherapy. Here, the antiproliferative effect of biocompatible montmorillonite (Mt) nanosheets on MDA-MB-231 and MCF-7 human breast cancer cells was evaluated by MTT assay, flow cytometry, and qRT-PCR. The results showed that the Mt IC

Indexed as

BentoniteBreast NeoplasmsCell ProliferationFemaleHumansMCF-7 CellsNecrosisTumor Suppressor Protein p53BentoniteTumor Suppressor Protein p53anticancer nanoparticlesantiproliferative effectbreast cancerMDA-MB-231montmorillonite

Identifiers

PMID38275825
PMCPMC10814472
OpenAlexW4391110666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.